0.3651

4.40% 0.0154

Relmada Therapeutics Inc (RLMD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.3497

Offen:

$0.3498

24-Stunden-Volumen:

1.20M

Relative Volume:

0.58

Marktkapitalisierung:

$21.41M

Einnahmen:

Nettoeinkommen (Verlust:

$-98.79M

KGV:

-0.1117

EPS:

-3.27

Netto-Cashflow:

$-51.66M

1W Leistung:

-43.40%

1M Leistung:

+20.46%

6M Leistung:

-89.54%

1J Leistung:

-90.19%

1-Tages-Spanne:

$0.3315

$0.3841

1-Wochen-Bereich:

$0.2675

$0.7409

52-Wochen-Spanne:

$0.2404

$4.47

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Firmenname

Relmada Therapeutics Inc

Sektor

Healthcare (1151)

Branche

Biotechnology (677)

Telefon

646 876 3459

Adresse

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Mitarbeiter

Twitter

@relmada

Nächster Verdiensttermin

2025-03-25

Neueste SEC-Einreichungen

RLMD's Discussions on Twitter

Vergleichen Sie RLMD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLMD	3.03	0	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.23	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	0.1601	355.59M	2.07B	-1.42B	-1.37B	-0.6765
MOBBW Mobilicom Limited Warrants	0.2199	318.40M	0	0	0	0.00
JUNE Dhandho Junoon Etf	11.50	211.65M	0	0	0	0.00
SHMD Schmid Group N V	4.00	156.75M	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-05	Herabstufung	Mizuho	Outperform → Neutral
2024-09-17	Hochstufung	Jefferies	Hold → Buy
2024-06-05	Herabstufung	Goldman	Neutral → Sell
2022-10-14	Herabstufung	Goldman	Buy → Neutral
2022-10-14	Herabstufung	Guggenheim	Buy → Neutral
2022-10-14	Herabstufung	Truist	Buy → Hold
2022-10-13	Herabstufung	Oppenheimer	Outperform → Perform
2021-11-18	Eingeleitet	Mizuho	Buy
2021-05-20	Fortgesetzt	Goldman	Buy
2020-10-28	Herabstufung	Goldman	Buy → Neutral
2020-07-14	Eingeleitet	Oppenheimer	Outperform
2020-05-04	Eingeleitet	SunTrust	Buy
2020-04-21	Eingeleitet	Goldman	Buy
2020-01-27	Eingeleitet	Jefferies	Buy
2020-01-10	Eingeleitet	SVB Leerink	Outperform
2019-12-16	Eingeleitet	Guggenheim	Buy

Alle ansehen

Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten

May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025

May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025

Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025

Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025

Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow

Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025

Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX

Apr 25, 2025

Apr 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times

Apr 24, 2025

Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan

Apr 24, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News

Apr 24, 2025

Apr 23, 2025

RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 23, 2025